AI Platform Advances Cancer Genomic Testing

SOPHiA GENETICS, announced that the Mount Sinai Health System, will adopt the AI- powered SOPHiA DDMTM Platform to advance cancer research and enhance genomic testing capabilities.

Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually. Mount Sinai’s Molecular Pathology team will leverage SOPHiA DDMTM to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The Platform is designed to enable detection and interpretation of a wide range of complex genomic variants while improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time.

By combining Mount Sinai’s clinical excellence with SOPHiA DDMTM’s advanced AI-powered analytics, the hospital will be equipped to interpret complex genomic datasets at scale and optimize laboratory resources, enabling teams to focus on direct patient care.

Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology of the Mount Sinai Health System, said: “The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDMTM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care.”

John Carey, Managing Director, North America, SOPHiA GENETICS, said: “Mount Sinai is widely regarded as one of the world’s leading centers for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology.”

By utilizing the SOPHiA DDMTM for Blood Cancers and SOPHiA DDMTM for Solid Tumors applications, Mount Sinai joins a growing network of more than 800 global institutions using SOPHiA GENETICS’ decentralized platform to accelerate precision medicine. This collaboration underscores SOPHiA GENETICS’ mission to democratize data-driven medicine,delivering scalable, cloud-native solutions that empower healthcare institutions to expand access to advanced genomic testing and improve patient outcomes worldwide.

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.